Border Medical Oncology

Phase	Trial	Trial Status	Site Status	Drug	NCT#
2	REGISTER: A multicentre phase 2 study of risk evaluation in GIST with selective therapy escalation for response	Completed	Closed	Imatinib, Nilotinib
2	A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) (ALT GIST)	Active, not recruiting	Active	Imatinib + Regorafenib	NCT02365441